Vivoryon Therapeutics NV Reports First Quarter 2024 Financial Results and Operating Progress May 23, 2024
Halle (Saale) / Munich, Germany, May 15th 2024 – Vivoryon Therapeutics NV (Euronext Amsterdam: VVY; NL00150002Q7) (Vivorillon), a clinical-stage company focused on the discovery and development of small molecule medicines to modulate the activity and stability of pathologically altered proteins, announced today The company announced its first quarter financial results and announced that it would provide corporate information. We will host public conference calls and webcasts.
Conference call details
Date: May 23, 2024
Time: 3:00 PM CEST / 9:00 AM EDT
Conference calls are available by phone and webcast.
A live audio webcast of the call will be available on Vivoryon's website at https://www.vivoryon.com/investors-news/news-and-events/presentations-webcasts/.
To join the conference call by telephone, participants can pre-register and receive dedicated dial-in details to easily and quickly access the call at the following website:
https://register.vevent.com/register/BI9aadfa99e014435493eca917a11150f1
We recommend that participants dial into the conference call 15 minutes before the scheduled start time to avoid late attendance.
###
About Vivoryon Therapeutics NV
Vivoryon is a clinical-stage biotechnology company focused on developing innovative small molecule-based medicines. Driven by a passion for breakthrough science and innovation, we are committed to transforming the lives of patients in need with serious diseases. We leverage our deep expertise in understanding post-translational modifications to develop medicines that modulate protein activity and stability as they change in disease settings. The company has established a pipeline of orally available small molecule inhibitors for a variety of indications, including Alzheimer's disease, inflammatory and fibrotic diseases including kidney, and cancer. www.vivoryon.com.
Vivoryon's forward-looking statements
This press release contains forward-looking statements, including, without limitation, statements regarding Vivoryon Therapeutics NV's (the “Company”) business strategy, management plans and future operating objectives, and estimates and projections regarding the market for the Company's products. It contains. Predictions and statements about when our products will be available. “anticipate”, “believe”, “estimate”, “expect”, “predict”, “intend”, “may”, “plan”, “anticipate”, “anticipate”; Words such as “should”, “anticipate” and similar expressions in connection with the Company are intended to identify such forward-looking statements. These forward-looking statements are not guarantees of future performance. Rather, they are based on management's current expectations and assumptions regarding future events and trends, economic and other future conditions. Forward-looking statements involve a number of known and unknown risks and uncertainties. These risks, uncertainties and other factors could materially and adversely affect the results and financial consequences of the plans and events described herein. Our results of operations, cash needs, financial condition, liquidity, prospects, future transactions, strategies or events may differ materially from those expressed or implied by such forward-looking statements and expectations. Accordingly, you should not place undue reliance on such forward-looking statements. This press release does not contain any risk factors. Certain risk factors that may affect our future financial results are discussed in our publicly available annual financial statements. This press release, including forward-looking statements, speaks only as of the date of this press release. We undertake no obligation to update the information or forward-looking statements contained herein, except as required by law to disclose such information.
For more information, please contact us below.
Investor contact information
Vivolion Therapeutics NV
Dr. Manuela Bader, Director of Investor Relations and Communications
Phone number: +49 (0)345 555 99 30
Email: IR@vivoryon.com
media contact
trophy communications
Valeria Fisher
Phone: +49 175 8041816
Email: vivoryon@trophic.eu
